The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
BUSINESS
Nipro to Strive for Stable Supply of Stemirac, 1st Stem Cell Therapy for Spinal Cord Injury
Nipro will strive to ensure stable supplies of Stemirac, the world’s first stem cell therapy for the treatment of spinal cord injury (SCI) that obtained conditional, time-limited approval in Japan on December 28, President Yoshihiko Sano vowed the same day.…
To read the full story
Related Article
- Stemirac Fetches 15 Million Yen Price Tag, Peak Sales Put at 3.7 Billion Yen
February 20, 2019
- Japan Gives Conditional OK to 1st Stem Cell Therapy for Spinal Cord Injury
December 28, 2018
- MHLW Panel Recommends Conditional Approval for Nipro’s Stem Cell Product for Spinal Cord Injury
November 26, 2018
BUSINESS
- Santen to Launch Myopia Drug in April; Will Its Private-Care Use Spread in Children?
March 21, 2025
- Otsuka/Taiho Look to Leverage Araris’ Linker Tech to Create 1st-in-Class ADCs
March 21, 2025
- Nippon Kayaku’s Humira Biosimilar Adds nr-axSpA Use
March 21, 2025
- New BMS Japan Chief Vows Bold Resource Allocation towards Doubling of Sales
March 21, 2025
- Datroway, Zeposia, and More Meds Now Available in Japan; Zepbound Launch Set for April 11
March 21, 2025
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…